Photo by Jean-Christophe Guillaume/Getty Images
Pfizer announced this week that their COVID-19 vaccine candidate has performed extremely well in their clinical trials, a reassuring sign that the months of investment and breakneck work on vaccines to protect people against the virus was going to pay off. That was never a sure thing — immunologists and virologists were pretty sure it’d be possible to make a vaccine that would block the coronavirus, but in pharmaceutical development, there’s no such thing as a guarantee.
This success makes it as important as ever to double down on efforts to slow the spread of COVID-19, which is currently raging out of control in most of the US. Back in March, when the pandemic was first picking up speed, public health officials stressed the importance…